BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6850
- TODAY'S CHANGE (%)0.0801 (13.2419%)
- Bid / Lots0.6900/ 14
- Ask / Lots0.7000/ 50
- Open / Previous Close0.6500 / 0.6049
- Day Range
- 52 Week Range
- Volume547,370
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 17219 | 0.6656 |
| 09:34 ET | 25111 | 0.6696 |
| 09:36 ET | 10725 | 0.65 |
| 09:41 ET | 1732 | 0.66 |
| 09:43 ET | 7195 | 0.6599 |
| 09:45 ET | 714 | 0.6473 |
| 09:48 ET | 700 | 0.6498 |
| 09:50 ET | 1447 | 0.6486 |
| 09:52 ET | 311 | 0.63495 |
| 09:54 ET | 8100 | 0.63 |
| 09:59 ET | 344 | 0.63 |
| 10:14 ET | 8600 | 0.634 |
| 10:15 ET | 3132 | 0.634 |
| 10:24 ET | 632 | 0.634 |
| 10:30 ET | 1699 | 0.634 |
| 10:32 ET | 160 | 0.6341 |
| 10:39 ET | 23061 | 0.66 |
| 10:46 ET | 1100 | 0.6491 |
| 10:48 ET | 400 | 0.64295 |
| 10:50 ET | 2316 | 0.6475 |
| 10:51 ET | 2300 | 0.6496 |
| 10:53 ET | 2500 | 0.6574 |
| 10:57 ET | 5385 | 0.6417 |
| 11:00 ET | 900 | 0.64605 |
| 11:02 ET | 700 | 0.6412 |
| 11:04 ET | 600 | 0.6472 |
| 11:06 ET | 400 | 0.6376 |
| 11:08 ET | 700 | 0.64 |
| 11:09 ET | 3300 | 0.6598 |
| 11:11 ET | 800 | 0.6599 |
| 11:18 ET | 3600 | 0.65 |
| 11:20 ET | 3513 | 0.65 |
| 11:22 ET | 2300 | 0.65 |
| 11:26 ET | 200 | 0.6598 |
| 11:29 ET | 700 | 0.6514 |
| 11:31 ET | 2353 | 0.6528 |
| 11:33 ET | 100 | 0.6527 |
| 11:36 ET | 1000 | 0.6528 |
| 11:38 ET | 200 | 0.6528 |
| 11:44 ET | 1000 | 0.6527 |
| 11:47 ET | 5300 | 0.6527 |
| 11:56 ET | 1000 | 0.652751 |
| 11:58 ET | 2200 | 0.6527 |
| 12:00 ET | 100 | 0.6527 |
| 12:05 ET | 200 | 0.6527 |
| 12:07 ET | 4400 | 0.6527 |
| 12:09 ET | 6235 | 0.6527 |
| 12:12 ET | 8600 | 0.6551 |
| 12:14 ET | 16418 | 0.6623 |
| 12:16 ET | 10143 | 0.6599 |
| 12:18 ET | 3500 | 0.6599 |
| 12:21 ET | 1000 | 0.6599 |
| 12:23 ET | 800 | 0.6599 |
| 12:30 ET | 350 | 0.66 |
| 12:34 ET | 300 | 0.6599 |
| 12:38 ET | 549 | 0.6599 |
| 12:43 ET | 2940 | 0.6501 |
| 12:45 ET | 1000 | 0.6502 |
| 12:52 ET | 332 | 0.6501 |
| 12:59 ET | 199 | 0.6502 |
| 01:06 ET | 100 | 0.66 |
| 01:08 ET | 1200 | 0.6502 |
| 01:14 ET | 1503 | 0.6552 |
| 01:17 ET | 3500 | 0.6504 |
| 01:21 ET | 1085 | 0.6689 |
| 01:24 ET | 1097 | 0.6688 |
| 01:26 ET | 1200 | 0.6599 |
| 01:28 ET | 400 | 0.6641 |
| 01:30 ET | 7000 | 0.6675 |
| 01:32 ET | 3800 | 0.669 |
| 01:33 ET | 100 | 0.6689 |
| 01:39 ET | 1022 | 0.66895 |
| 01:44 ET | 5600 | 0.6689 |
| 01:46 ET | 22900 | 0.6669 |
| 01:48 ET | 2134 | 0.66875 |
| 01:50 ET | 1236 | 0.6689 |
| 01:51 ET | 7800 | 0.65 |
| 01:55 ET | 6556 | 0.6501 |
| 02:11 ET | 1100 | 0.6687 |
| 02:13 ET | 1000 | 0.6505 |
| 02:18 ET | 275 | 0.6532 |
| 02:29 ET | 1200 | 0.6505 |
| 02:31 ET | 210 | 0.6602 |
| 02:36 ET | 700 | 0.6674 |
| 02:38 ET | 1300 | 0.668201 |
| 02:51 ET | 10099 | 0.6642 |
| 02:58 ET | 13552 | 0.66 |
| 03:03 ET | 372 | 0.665999 |
| 03:07 ET | 457 | 0.6719 |
| 03:09 ET | 800 | 0.6661 |
| 03:18 ET | 19281 | 0.6797 |
| 03:20 ET | 412 | 0.68 |
| 03:21 ET | 820 | 0.67305 |
| 03:23 ET | 3264 | 0.6661 |
| 03:25 ET | 100 | 0.675 |
| 03:27 ET | 3300 | 0.6662 |
| 03:30 ET | 430 | 0.6662 |
| 03:34 ET | 1100 | 0.6662 |
| 03:36 ET | 9825 | 0.675 |
| 03:39 ET | 1300 | 0.67995 |
| 03:41 ET | 493 | 0.67995 |
| 03:43 ET | 2666 | 0.68 |
| 03:45 ET | 100 | 0.68 |
| 03:48 ET | 13895 | 0.6799 |
| 03:50 ET | 5815 | 0.68 |
| 03:52 ET | 25288 | 0.68 |
| 03:54 ET | 3654 | 0.685 |
| 03:56 ET | 17593 | 0.6849 |
| 03:57 ET | 27691 | 0.6894 |
| 03:59 ET | 11475 | 0.685 |
Yesterday
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, from 7:00AM ET on Friday May 24, 2024 by Dow Jones
7:00AM ET on Friday May 24, 2024 by Dow Jones
May 22, 2024
BioLineRx to Report First Quarter 2024 Results on May 28, 2024, from 7:00AM ET on Wednesday May 22, 2024 by Dow Jones
7:00AM ET on Wednesday May 22, 2024 by Dow Jones
May 17, 2024
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification, from 5:00PM ET on Friday May 17, 2024 by Dow Jones
5:00PM ET on Friday May 17, 2024 by Dow Jones
May 6, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.6M | -0.7x | --- |
Kezar Life Sciences Inc | 51.3M | -0.5x | --- |
Evogene Ltd | 41.5M | -1.8x | --- |
Dyadic International Inc | 57.0M | -7.2x | --- |
Kronos Bio Inc | 45.4M | -0.4x | --- |
Palatin Technologies Inc | 32.3M | -0.8x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.6M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 11.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
